J INTS BIO Presents Interim Findings from Phase 1 / 2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

J INTS BIO New York Spain South Korea California

View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-presents-interim-findings-from-phase-12-clinical-trial-of-4th-generation-egfr-tki-jin-a02-in-nsclc-a-potential-breakthrough-in-overcoming-acquired-resistance-to-targeted-therapy-302285488.html